What inspires us to be innovators and disruptors? It’s the 38 million people living with HIV around the world. Our mission is to leave no person living with HIV behind and that’s why we won't stop innovating
Our goal is to minimise the impact of HIV on people’s lives by treating, preventing and ultimately curing the disease. To achieve this, we are developing HIV treatment and prevention options that have the potential to greatly reduce the amount of medicines a person living with HIV has to take, in some cases down from every day to only six days each year.
We seek and include patient and provider insights in both our pipeline and portfolio strategies. We have more than 50 active collaborations worldwide with pharmaceutical and biotechnology companies, government agencies, academic institutions and not-for-profit organisations. In addition to our active collaborations, we support more than 200 studies around the world, accelerating our ability to develop a robust and diverse pipeline for people living with HIV/AIDS.
Our innovative partnerships
We have an exclusive licensing agreement with Shionogi for a third-generation integrase inhibitor, a pre-clinical candidate that will give us the potential to offer medicines with longer dosing intervals than the current standard of care.
We have also announced an exclusive licensing agreement with Halozyme for its drug delivery technology. By creating a temporary expansion under the skin, increased volumes of medicine can be delivered without pain or discomfort. This technology gives us the potential to increase dosing intervals from every two months to as long as six months.
Our ultimate goal remains to find a cure for HIV. We are continuing to progress our unique industry/academic partnership with the University of North Carolina at Chapel Hill through our jointly-owned QURA Therapeutics.